Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials
One of the biggest challenges for analgesic drug development is how to decide if a potential analgesic candidate will work in humans. What preclinical data are the most convincing, incentivizing and most predictive of success? Such a predicament is not unique to analgesics, and the pain field has ce...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.705743/full |
| _version_ | 1831585755201273856 |
|---|---|
| author | Michael J. Iadarola Dorothy Cimino Brown Alexis Nahama Matthew R. Sapio Andrew J. Mannes |
| author_facet | Michael J. Iadarola Dorothy Cimino Brown Alexis Nahama Matthew R. Sapio Andrew J. Mannes |
| author_sort | Michael J. Iadarola |
| collection | DOAJ |
| description | One of the biggest challenges for analgesic drug development is how to decide if a potential analgesic candidate will work in humans. What preclinical data are the most convincing, incentivizing and most predictive of success? Such a predicament is not unique to analgesics, and the pain field has certain advantages over drug development efforts in areas like neuropsychiatry where the etiological origins are either unknown or difficult to ascertain. For pain, the origin of the problem frequently is known, and the causative peripheral tissue insult might be observable. The main conundrum centers around evaluation of translational cell- and rodent-based results. While cell and rodent models are undeniably important first steps for screening, probing mechanism of action, and understanding factors of adsorption, distribution metabolism and excretion, two questions arise from such studies. First, are they reliable indicators of analgesic performance of a candidate drug in human acute and chronic pain? Second, what additional model systems might be capable of increasing translational confidence? We address this second question by assessing, primarily, the companion canine model, which can provide particularly strong predictive information for candidate analgesic agents in humans. This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin. Our experience, to date, is that rodent models might be very well suited for acute pain translation, but companion canine models, and other large animal studies, can augment initial discovery research using rodent models for neuropathic or chronic pain. The larger animal models also provide strong translational predictive capacity for analgesic performance in humans, better predict dosing parameters for human trials and provide insight into behavior changes (bladder, bowel, mood, etc.) that are not readily assessed in laboratory animals. They are, however, not without problems that can be encountered with any experimental drug treatment or clinical trial. It also is important to recognize that pain treatment is a major veterinary concern and is an intrinsically worthwhile endeavor for animals as well as humans. |
| first_indexed | 2024-12-17T21:23:09Z |
| format | Article |
| id | doaj.art-f133d0c8396a4eaea72dbdaf7ead34e4 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T21:23:09Z |
| publishDate | 2021-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-f133d0c8396a4eaea72dbdaf7ead34e42022-12-21T21:32:07ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-08-011210.3389/fphar.2021.705743705743Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical TrialsMichael J. Iadarola0Dorothy Cimino Brown1Alexis Nahama2Matthew R. Sapio3Andrew J. Mannes4Department of Perioperative Medicine, Clinical Center, NIH, Bethesda, MD, United StatesElanco Animal Health, Greenfield, IN, United StatesArk Animal Health, San Diego, CA, United StatesDepartment of Perioperative Medicine, Clinical Center, NIH, Bethesda, MD, United StatesDepartment of Perioperative Medicine, Clinical Center, NIH, Bethesda, MD, United StatesOne of the biggest challenges for analgesic drug development is how to decide if a potential analgesic candidate will work in humans. What preclinical data are the most convincing, incentivizing and most predictive of success? Such a predicament is not unique to analgesics, and the pain field has certain advantages over drug development efforts in areas like neuropsychiatry where the etiological origins are either unknown or difficult to ascertain. For pain, the origin of the problem frequently is known, and the causative peripheral tissue insult might be observable. The main conundrum centers around evaluation of translational cell- and rodent-based results. While cell and rodent models are undeniably important first steps for screening, probing mechanism of action, and understanding factors of adsorption, distribution metabolism and excretion, two questions arise from such studies. First, are they reliable indicators of analgesic performance of a candidate drug in human acute and chronic pain? Second, what additional model systems might be capable of increasing translational confidence? We address this second question by assessing, primarily, the companion canine model, which can provide particularly strong predictive information for candidate analgesic agents in humans. This statement is mainly derived from our studies with resiniferatoxin (RTX) a potent TRPV1 agonist but also from protein therapeutics using a conjugate of Substance P and saporin. Our experience, to date, is that rodent models might be very well suited for acute pain translation, but companion canine models, and other large animal studies, can augment initial discovery research using rodent models for neuropathic or chronic pain. The larger animal models also provide strong translational predictive capacity for analgesic performance in humans, better predict dosing parameters for human trials and provide insight into behavior changes (bladder, bowel, mood, etc.) that are not readily assessed in laboratory animals. They are, however, not without problems that can be encountered with any experimental drug treatment or clinical trial. It also is important to recognize that pain treatment is a major veterinary concern and is an intrinsically worthwhile endeavor for animals as well as humans.https://www.frontiersin.org/articles/10.3389/fphar.2021.705743/fullcancer painosteoarthritis painresiniferatoxin (RTX)TRPV1transient receptor potential vanilloid type 1 receptoropioid |
| spellingShingle | Michael J. Iadarola Dorothy Cimino Brown Alexis Nahama Matthew R. Sapio Andrew J. Mannes Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials Frontiers in Pharmacology cancer pain osteoarthritis pain resiniferatoxin (RTX) TRPV1 transient receptor potential vanilloid type 1 receptor opioid |
| title | Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials |
| title_full | Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials |
| title_fullStr | Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials |
| title_full_unstemmed | Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials |
| title_short | Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials |
| title_sort | pain treatment in the companion canine model to validate rodent results and incentivize the transition to human clinical trials |
| topic | cancer pain osteoarthritis pain resiniferatoxin (RTX) TRPV1 transient receptor potential vanilloid type 1 receptor opioid |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.705743/full |
| work_keys_str_mv | AT michaeljiadarola paintreatmentinthecompanioncaninemodeltovalidaterodentresultsandincentivizethetransitiontohumanclinicaltrials AT dorothyciminobrown paintreatmentinthecompanioncaninemodeltovalidaterodentresultsandincentivizethetransitiontohumanclinicaltrials AT alexisnahama paintreatmentinthecompanioncaninemodeltovalidaterodentresultsandincentivizethetransitiontohumanclinicaltrials AT matthewrsapio paintreatmentinthecompanioncaninemodeltovalidaterodentresultsandincentivizethetransitiontohumanclinicaltrials AT andrewjmannes paintreatmentinthecompanioncaninemodeltovalidaterodentresultsandincentivizethetransitiontohumanclinicaltrials |